Clinical Trial Search

Primary: Change in Pulse Wave Velocity (PWV) — -0.25; -0.16 m/s

Primary: Mortality at 30 Days — 1; 7; 3; 2 participants

Primary: Emergency Room Visits — 40; 33 Emergency Room Visits

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Global Left Ventricular Function — 3.5; 4.4; 2.8; 1.7 percentage of ejection fraction — p=0.959

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality — 6.58; 5.85 Pt with events/100 pt-years at risk — p=0.2061

Primary: 24-hour Heart Rate — 83.8; 78.5 beats per minute

Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants

Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05

Primary: The Feasibility of Intracoronary Infusion of SSO2 Therapy — 20 participants

Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi in mL/m2) at Day 90 Post Myocardial Infarction (MI) — 5.48; 5.09 mL/m2 — p=0.4239

Primary: Hospital Time to Treatment for Patients With Unstable Angina/Non-STEMI — 23; 31 minutes

Primary: MACE (Major Adverse Cardiac Events) — 405; 345 Participants

Primary: Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling — -5.4; 1.2 Percent Change

Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units

Primary: Degree of Platelet Inhibition Measured — 248.3; 145.2 Platelet Reactivity Units (PRU)

Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF

Primary: Thrombus Volume (mm^3) — 9.8; 4.8; 7.7 mm^3

Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…

Primary: Number of Participants Readmitted Within 30-days Post Hospital Discharge — 13; 145 Participants — p=0.018

Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants

Primary: Number of Death — 417; 137; 552 Participants

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date — 66.37; 70.62 Adjusted monthly % of days covered

Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05

Primary: Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention — 100; 100 Percent diameter…

Primary: Infarct Size in the Territory of the Infarct Related Artery — 15.8; 15.0 percentage of LV mass

Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.